Jane S. Ricciuti, RPh, MS


April 22, 2003

In This Article

Immunosuppressive Agents

(mycophenolate mofetil hydrochloride) Intravenous/Oral Suspension/Capsules/Tablets

Manufacturer: Hoffman La-Roche, Inc

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 2/28/03)

Adverse Effects: The following statements were added to the "Adverse Reactions" section of the CellCept product labeling:

  • Patients receiving CellCept alone or as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin.

  • All transplant patients are at increased risk of opportunistic infections. The risk increases with total immunosuppressive load.

CellCept (mycophenolate mofetil hydrochloride) Labeling

CellCept (mycophenolate mofetil hydrochloride)


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.